The immune checkpoint inhibitors (ICIs) that target the PD-L1 and programmed death-1 (PD-1) could promote immunogenicity and modify the tumor microenvironment (TME) to enhance the therapeutic effects. This evidence concerns the gene CD274 and neoplasm.